Histone deacetylase inhibitors (HDIs) have found a wide variety of medicinal uses and are most noted for their specific apoptotic action towards cancer cells. Several hydroxamate HDIs have since been moved on to phase 1 and 2 clinical drug trials, with one having already been approved for treatment of advanced cutaneous T-cell lymphoma. Trichostatin A is one of the most potent known naturally-occurring inhibitors of histone deacetylase. Unfortunately for researchers, the syntheses that have been reported are both long and difficult, which leads to a low overall yield and therefore to a prohibitively expensive product, limiting its medicinal potential. This work builds on several previously published syntheses and shows a more efficient synthesis of Trichostatin A, which will make it more available for use in a variety of treatments.
","abstract_html":"<p>Histone deacetylase inhibitors (HDIs) have found a wide variety of medicinal uses and are most noted for their specific apoptotic action towards cancer cells. Several hydroxamate HDIs have since been moved on to phase 1 and 2 clinical drug trials, with one having already been approved for treatment of advanced cutaneous T-cell lymphoma. Trichostatin A is one of the most potent known naturally-occurring inhibitors of histone deacetylase. Unfortunately for researchers, the syntheses that have been reported are both long and difficult, which leads to a low overall yield and therefore to a prohibitively expensive product, limiting its medicinal potential. This work builds on several previously published syntheses and shows a more efficient synthesis of Trichostatin A, which will make it more available for use in a variety of treatments.</p>","abstract_has_math":false,"creators":["Colombo, Joseph"],"institution":null,"degree_name":"Master of Science (MS)","degree_level":"Open Access Thesis","degree_discipline":"Chemistry","degree_department":null,"school":null,"contributors":["Andrei Kornilov, PhD","Harriet Lindsay, PhD","Cory Emal, PhD"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2009,"date_issued":"2009-01-01T08:00:00Z","date_published":"2009-01-01T08:00:00Z","updated_at":"2026-07-24T02:16:36Z","subjects":["Enzyme inhibitors","Pharmaceutical chemistry","Chemistry"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://commons.emich.edu/theses/237","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Andrei Kornilov, PhD","Harriet Lindsay, PhD","Cory Emal, PhD"]},{"key":"dc:creator","label":"Author","values":["Colombo, Joseph"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Open Access Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science (MS)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Enzyme inhibitors","Pharmaceutical chemistry","Chemistry"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://commons.emich.edu/theses/237"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Histone deacetylase inhibitors (HDIs) have found a wide variety of medicinal uses and are most noted for their specific apoptotic action towards cancer cells. Several hydroxamate HDIs have since been moved on to phase 1 and 2 clinical drug trials, with one having already been approved for treatment of advanced cutaneous T-cell lymphoma. Trichostatin A is one of the most potent known naturally-occurring inhibitors of histone deacetylase. Unfortunately for researchers, the syntheses that have been reported are both long and difficult, which leads to a low overall yield and therefore to a prohibitively expensive product, limiting its medicinal potential. This work builds on several previously published syntheses and shows a more efficient synthesis of Trichostatin A, which will make it more available for use in a variety of treatments.
"]},{"key":"dc:title","label":"Title","values":["An improved synthesis of the HDAC inhibitor trichostatin A"]}]}],"canonical_facts":{"dc:contributor":["Andrei Kornilov, PhD","Harriet Lindsay, PhD","Cory Emal, PhD"],"dc:creator":["Colombo, Joseph"],"dc:description.abstract":["Histone deacetylase inhibitors (HDIs) have found a wide variety of medicinal uses and are most noted for their specific apoptotic action towards cancer cells. Several hydroxamate HDIs have since been moved on to phase 1 and 2 clinical drug trials, with one having already been approved for treatment of advanced cutaneous T-cell lymphoma. Trichostatin A is one of the most potent known naturally-occurring inhibitors of histone deacetylase. Unfortunately for researchers, the syntheses that have been reported are both long and difficult, which leads to a low overall yield and therefore to a prohibitively expensive product, limiting its medicinal potential. This work builds on several previously published syntheses and shows a more efficient synthesis of Trichostatin A, which will make it more available for use in a variety of treatments.
"],"dc:identifier":["https://commons.emich.edu/theses/237"],"dc:subject":["Enzyme inhibitors","Pharmaceutical chemistry","Chemistry"],"dc:title":["An improved synthesis of the HDAC inhibitor trichostatin A"],"thesis:degree_discipline":["Chemistry"],"thesis:degree_level":["Open Access Thesis"],"thesis:degree_name":["Master of Science (MS)"]},"updated_at":"2026-07-24T02:16:36Z"}